$PPHM News Apollo slammed on education departm
Post# of 89377
Posted On: 01/19/2015 12:52:22 PM
$PPHM News
Apollo slammed on education department review 5:09 p.m. July 14, 2014 - Tom Bemis
Peregrine plunges on test data 3:17 p.m. June 27, 2013 - Russ Britt
Small-cap makes a splash with FDA nod for cancer drug 2:16 p.m. May 20, 2013 - Russ Britt
Peregrine drug shows promise in pancreatic cancer 12:17 p.m. Feb. 13, 2013 - MarketWatch.com
In focus: Bullish, but overbought 7:06 p.m. Jan. 9, 2013 - Lawrence G. McMillan
Hedge funds are bullish on these stocks 10:57 a.m. Dec. 5, 2012 - Insider Monkey
Peregrine, FDA agree on brain-cancer drug study 10:56 a.m. Dec. 5, 2012 - MarketWatch.com
Drug trial contractors improve efficiency 9:24 a.m. Nov. 16, 2012 - MarketWatch.com
Monday’s biggest gaining and declining stocks 5:42 p.m. Sept. 25, 2012 - Greg Morcroft
Tuesday’s biggest gaining and declining stocks 4:09 p.m. Sept. 25, 2012 - Greg Morcroft
Peregrine Pharma down 86% after test data review 7:27 a.m. Sept. 24, 2012 - Steve Gelsi
Peregrine Pharma down 86% in premarket 7:18 a.m. Sept. 24, 2012 - Steve Gelsi
Peregrine reviewing Bavituximab results 6:42 a.m. Sept. 24, 2012 - Greg Morcroft
Some previous Bavituximab data not valid
eregrine 6:42 a.m. Sept. 24, 2012 - Greg Morcroft
Monday’s biggest gaining and declining stocks 1:42 p.m. Sept. 10, 2012 - MarketWatch
Regions Financial, Williams-Sonoma hit 52-week highs; Intel, Cisco active 10:11 a.m. Sept. 10, 2012 - blogs.marketwatch.com
Stocks to watch Monday: AIG, Michael Kors, Sears 5:41 a.m. Sept. 10, 2012 - MarketWatch
Peregrine rallies on bavituximab lung-cancer data 12:29 p.m. Sept. 7, 2012 - MarketWatch.com
Monday’s biggest gaining & declining stocks 1:53 p.m. Aug. 27, 2012 - MarketWatch
Peregrine Pharma slides 12% after negative report 1:21 p.m. Aug. 27, 2012 - Val Brickates Kennedy
12 Biotech Stocks to Watch in 2015 8:45 a.m. Jan. 9, 2015 - InvestorPlace.com
Peregrine Pharmaceuticals Series E Preferred Stock Shares Cross 12% Yield Mark 2:14 p.m. Dec. 18, 2014 - TheStreet.com
Ex-Div Reminder For Peregrine Pharmaceuticals Series E Convertible Preferred Stock 2:11 p.m. Dec. 15, 2014 - TheStreet.com
Peregrine Pharmaceuticals' (PPHM) CEO Steven King on Q2 2015 Results - Earnings Call Transcript 4:39 a.m. Dec. 11, 2014 - Seeking Alpha
Peregrine Pharmaceuticals (PPHM) Q2 2015 Results - Earnings Call Webcast 4:25 p.m. Dec. 10, 2014 - Seeking Alpha
10-Q: PEREGRINE PHARMACEUTICALS INC 4:23 p.m. Dec. 10, 2014 - Edgar Online - (EDG = 10Q, 10K)
Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining 7:59 a.m. Nov. 13, 2014 - Seeking Alpha
Peregrine Pharmaceuticals (PPHM) Jumps: Stock Rises 10.7% - Tale of the Tape 8:39 a.m. Oct. 16, 2014 - Zacks.com
Peregrine Pharmaceuticals' Q1 Loss Wider than Expected - Analyst Blog 8:00 a.m. Sept. 10, 2014 - Zacks.com
Peregrine Pharmaceuticals' (PPHM) CEO Steven King on Q1 2015 Results - Earnings Call Transcript 6:53 p.m. Sept. 9, 2014 - Seeking Alpha
10-Q: PEREGRINE PHARMACEUTICALS INC 3:29 p.m. Sept. 9, 2014 - Edgar Online - (EDG = 10Q, 10K)
Peregrine Pharmaceuticals (PPHM) Q1 2015 Results - Earnings Call Webcast 3:25 p.m. Sept. 9, 2014 - Seeking Alpha
Tekmira Pharmaceuticals Corp. Is More Than Just A Short-Term Trade 2:12 p.m. Aug. 27, 2014 - Seeking Alpha
Cel-Sci Is A Leader In The I-O Class Of Cancer Therapies 9:43 a.m. Aug. 12, 2014 - Seeking Alpha
Peregrine Pharmaceuticals' Q4 Loss Narrower than Expected - Analyst Blog 10:00 a.m. July 15, 2014 - Zacks.com
Peregrine Pharmaceuticals' (PPHM) CEO Steven King on Q4 2014 Results - Earnings Call Transcript 9:21 p.m. July 14, 2014 - Seeking Alpha
10-K: PEREGRINE PHARMACEUTICALS INC 4:00 p.m. July 14, 2014 - Edgar Online - (EDG = 10Q, 10K)
More on Peregrine fiscal Q4 and fiscal year results 3:26 p.m. July 14, 2014 - Seeking Alpha
Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events 8:30 a.m. July 14, 2014 - TheStreet.com
First Week Of January 2015 Options Trading For Peregrine Pharmaceuticals (PPHM) 10:09 a.m. May 20, 2014 - TheStreet.com
Phase II Clinical Data of Peregrine Pharmaceuticals' Bavituximab in Combination With Sorafenib Presented at ASCO Gastrointestinal Cancers Symposium 9:31 a.m. Jan. 16, 2015 - Marketwired
Data to Be Presented at 2014 San Antonio Breast Cancer Symposium Demonstrate Immune-Stimulatory Properties of Peregrine Pharmaceuticals' Bavituximab in Models of Breast Cancer 8:01 a.m. Dec. 12, 2014 - Marketwired
Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2015 Financial Results and Recent Developments 4:03 p.m. Dec. 10, 2014 - Marketwired
Avid Bioservices Announces Expansion of cGMP Manufacturing Capacity 8:06 a.m. Dec. 10, 2014 - Marketwired
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock 4:00 p.m. Dec. 9, 2014 - Marketwired
Peregrine Pharmaceuticals to Report Second Quarter Fiscal 2015 Financial Results After Market on December 10, 2014 4:01 p.m. Dec. 3, 2014 - Marketwired
Phase II Clinical Data Presented at SITC Annual Meeting Support Immunotherapeutic Mechanism of Action of Peregrine Pharmaceuticals' Bavituximab in Liver Cancer 7:32 a.m. Nov. 10, 2014 - Marketwired
Data to Be Presented at the SITC Annual Meeting Support Synergy of PS-Targeting and Anti-CTLA-4 Immunotherapies to Enhance Anti-Tumor Treatments in Melanoma 7:45 a.m. Nov. 7, 2014 - Marketwired
Promising Data Presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology From an Investigator-Sponsored Trial of Peregrine Pharmaceuticals' Bavituximab in Combination With Pemetrexed and Carboplatin in Front-Line Non-Small Cell Lung Cancer 8:43 a.m. Oct. 30, 2014 - Marketwired
Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 8:00 a.m. Oct. 24, 2014 - PR Newswire - PRF
Data to Be Published in the Journal of Immunology Research Support Phosphatidylserine (PS) as a Potential Target in Ebola Infection 7:05 a.m. Oct. 15, 2014 - Marketwired
Data to Be Presented at CRI Immunotherapy Conference Show PS-Targeting Antibodies Enhance the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Decreasing Levels of Myeloid Derived Suppressor Cells (MDSC) in the Tumor Microenvironment 7:03 a.m. Oct. 6, 2014 - Marketwire
Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2015 Financial Results and Recent Developments 3:01 p.m. Sept. 9, 2014 - Marketwire
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock 3:00 p.m. Sept. 8, 2014 - Marketwire
Peregrine Pharmaceuticals to Report First Quarter Fiscal Year 2015 Financial Results After Market Close on September 9, 2014 3:01 p.m. Sept. 2, 2014 - Marketwire
Preclinical Data Presented at Annual Immunotherapies and Vaccine Summit Show That the Combination of Peregrine Pharmaceuticals' PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce Breast Cancer Progression 7:03 a.m. Aug. 11, 2014 - Marketwire
Small companies lead the I-O class of Cancer Therapies 7:03 a.m. Aug. 8, 2014 - ACCESSWIRE
Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma 8:00 a.m. Aug. 1, 2014 - PR Newswire - PRF
Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal Year 2014 Financial Results and Recent Developments 3:01 p.m. July 14, 2014 - Marketwire
Peregrine Pharmaceuticals to Report Fourth Quarter and Year-End Fiscal 2014 Financial Results After Market on July 14, 2014 3:00 p.m. July 7, 2014 - Marketwire
Apollo slammed on education department review 5:09 p.m. July 14, 2014 - Tom Bemis
Peregrine plunges on test data 3:17 p.m. June 27, 2013 - Russ Britt
Small-cap makes a splash with FDA nod for cancer drug 2:16 p.m. May 20, 2013 - Russ Britt
Peregrine drug shows promise in pancreatic cancer 12:17 p.m. Feb. 13, 2013 - MarketWatch.com
In focus: Bullish, but overbought 7:06 p.m. Jan. 9, 2013 - Lawrence G. McMillan
Hedge funds are bullish on these stocks 10:57 a.m. Dec. 5, 2012 - Insider Monkey
Peregrine, FDA agree on brain-cancer drug study 10:56 a.m. Dec. 5, 2012 - MarketWatch.com
Drug trial contractors improve efficiency 9:24 a.m. Nov. 16, 2012 - MarketWatch.com
Monday’s biggest gaining and declining stocks 5:42 p.m. Sept. 25, 2012 - Greg Morcroft
Tuesday’s biggest gaining and declining stocks 4:09 p.m. Sept. 25, 2012 - Greg Morcroft
Peregrine Pharma down 86% after test data review 7:27 a.m. Sept. 24, 2012 - Steve Gelsi
Peregrine Pharma down 86% in premarket 7:18 a.m. Sept. 24, 2012 - Steve Gelsi
Peregrine reviewing Bavituximab results 6:42 a.m. Sept. 24, 2012 - Greg Morcroft
Some previous Bavituximab data not valid
eregrine 6:42 a.m. Sept. 24, 2012 - Greg Morcroft Monday’s biggest gaining and declining stocks 1:42 p.m. Sept. 10, 2012 - MarketWatch
Regions Financial, Williams-Sonoma hit 52-week highs; Intel, Cisco active 10:11 a.m. Sept. 10, 2012 - blogs.marketwatch.com
Stocks to watch Monday: AIG, Michael Kors, Sears 5:41 a.m. Sept. 10, 2012 - MarketWatch
Peregrine rallies on bavituximab lung-cancer data 12:29 p.m. Sept. 7, 2012 - MarketWatch.com
Monday’s biggest gaining & declining stocks 1:53 p.m. Aug. 27, 2012 - MarketWatch
Peregrine Pharma slides 12% after negative report 1:21 p.m. Aug. 27, 2012 - Val Brickates Kennedy
12 Biotech Stocks to Watch in 2015 8:45 a.m. Jan. 9, 2015 - InvestorPlace.com
Peregrine Pharmaceuticals Series E Preferred Stock Shares Cross 12% Yield Mark 2:14 p.m. Dec. 18, 2014 - TheStreet.com
Ex-Div Reminder For Peregrine Pharmaceuticals Series E Convertible Preferred Stock 2:11 p.m. Dec. 15, 2014 - TheStreet.com
Peregrine Pharmaceuticals' (PPHM) CEO Steven King on Q2 2015 Results - Earnings Call Transcript 4:39 a.m. Dec. 11, 2014 - Seeking Alpha
Peregrine Pharmaceuticals (PPHM) Q2 2015 Results - Earnings Call Webcast 4:25 p.m. Dec. 10, 2014 - Seeking Alpha
10-Q: PEREGRINE PHARMACEUTICALS INC 4:23 p.m. Dec. 10, 2014 - Edgar Online - (EDG = 10Q, 10K)
Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining 7:59 a.m. Nov. 13, 2014 - Seeking Alpha
Peregrine Pharmaceuticals (PPHM) Jumps: Stock Rises 10.7% - Tale of the Tape 8:39 a.m. Oct. 16, 2014 - Zacks.com
Peregrine Pharmaceuticals' Q1 Loss Wider than Expected - Analyst Blog 8:00 a.m. Sept. 10, 2014 - Zacks.com
Peregrine Pharmaceuticals' (PPHM) CEO Steven King on Q1 2015 Results - Earnings Call Transcript 6:53 p.m. Sept. 9, 2014 - Seeking Alpha
10-Q: PEREGRINE PHARMACEUTICALS INC 3:29 p.m. Sept. 9, 2014 - Edgar Online - (EDG = 10Q, 10K)
Peregrine Pharmaceuticals (PPHM) Q1 2015 Results - Earnings Call Webcast 3:25 p.m. Sept. 9, 2014 - Seeking Alpha
Tekmira Pharmaceuticals Corp. Is More Than Just A Short-Term Trade 2:12 p.m. Aug. 27, 2014 - Seeking Alpha
Cel-Sci Is A Leader In The I-O Class Of Cancer Therapies 9:43 a.m. Aug. 12, 2014 - Seeking Alpha
Peregrine Pharmaceuticals' Q4 Loss Narrower than Expected - Analyst Blog 10:00 a.m. July 15, 2014 - Zacks.com
Peregrine Pharmaceuticals' (PPHM) CEO Steven King on Q4 2014 Results - Earnings Call Transcript 9:21 p.m. July 14, 2014 - Seeking Alpha
10-K: PEREGRINE PHARMACEUTICALS INC 4:00 p.m. July 14, 2014 - Edgar Online - (EDG = 10Q, 10K)
More on Peregrine fiscal Q4 and fiscal year results 3:26 p.m. July 14, 2014 - Seeking Alpha
Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events 8:30 a.m. July 14, 2014 - TheStreet.com
First Week Of January 2015 Options Trading For Peregrine Pharmaceuticals (PPHM) 10:09 a.m. May 20, 2014 - TheStreet.com
Phase II Clinical Data of Peregrine Pharmaceuticals' Bavituximab in Combination With Sorafenib Presented at ASCO Gastrointestinal Cancers Symposium 9:31 a.m. Jan. 16, 2015 - Marketwired
Data to Be Presented at 2014 San Antonio Breast Cancer Symposium Demonstrate Immune-Stimulatory Properties of Peregrine Pharmaceuticals' Bavituximab in Models of Breast Cancer 8:01 a.m. Dec. 12, 2014 - Marketwired
Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2015 Financial Results and Recent Developments 4:03 p.m. Dec. 10, 2014 - Marketwired
Avid Bioservices Announces Expansion of cGMP Manufacturing Capacity 8:06 a.m. Dec. 10, 2014 - Marketwired
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock 4:00 p.m. Dec. 9, 2014 - Marketwired
Peregrine Pharmaceuticals to Report Second Quarter Fiscal 2015 Financial Results After Market on December 10, 2014 4:01 p.m. Dec. 3, 2014 - Marketwired
Phase II Clinical Data Presented at SITC Annual Meeting Support Immunotherapeutic Mechanism of Action of Peregrine Pharmaceuticals' Bavituximab in Liver Cancer 7:32 a.m. Nov. 10, 2014 - Marketwired
Data to Be Presented at the SITC Annual Meeting Support Synergy of PS-Targeting and Anti-CTLA-4 Immunotherapies to Enhance Anti-Tumor Treatments in Melanoma 7:45 a.m. Nov. 7, 2014 - Marketwired
Promising Data Presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology From an Investigator-Sponsored Trial of Peregrine Pharmaceuticals' Bavituximab in Combination With Pemetrexed and Carboplatin in Front-Line Non-Small Cell Lung Cancer 8:43 a.m. Oct. 30, 2014 - Marketwired
Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 8:00 a.m. Oct. 24, 2014 - PR Newswire - PRF
Data to Be Published in the Journal of Immunology Research Support Phosphatidylserine (PS) as a Potential Target in Ebola Infection 7:05 a.m. Oct. 15, 2014 - Marketwired
Data to Be Presented at CRI Immunotherapy Conference Show PS-Targeting Antibodies Enhance the Anti-Tumor Activity of Immune Checkpoint Inhibitors by Decreasing Levels of Myeloid Derived Suppressor Cells (MDSC) in the Tumor Microenvironment 7:03 a.m. Oct. 6, 2014 - Marketwire
Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2015 Financial Results and Recent Developments 3:01 p.m. Sept. 9, 2014 - Marketwire
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock 3:00 p.m. Sept. 8, 2014 - Marketwire
Peregrine Pharmaceuticals to Report First Quarter Fiscal Year 2015 Financial Results After Market Close on September 9, 2014 3:01 p.m. Sept. 2, 2014 - Marketwire
Preclinical Data Presented at Annual Immunotherapies and Vaccine Summit Show That the Combination of Peregrine Pharmaceuticals' PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce Breast Cancer Progression 7:03 a.m. Aug. 11, 2014 - Marketwire
Small companies lead the I-O class of Cancer Therapies 7:03 a.m. Aug. 8, 2014 - ACCESSWIRE
Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma 8:00 a.m. Aug. 1, 2014 - PR Newswire - PRF
Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal Year 2014 Financial Results and Recent Developments 3:01 p.m. July 14, 2014 - Marketwire
Peregrine Pharmaceuticals to Report Fourth Quarter and Year-End Fiscal 2014 Financial Results After Market on July 14, 2014 3:00 p.m. July 7, 2014 - Marketwire
(0)
(0)